NCT07118527View on ClinicalTrials.gov

A Phase III Study of SHR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Untreated Patients With Gastric or Gastroesophageal Junction Adenocarcinoma

PHASE3RecruitingINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

August 18, 2025

Primary Completion Date

October 31, 2030

Study Completion Date

October 31, 2030

Conditions
Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma
Interventions
DRUG

SHR-A1811 + Adebrelimab Injection + Capecitabine Tablets or Fluorouracil Injection

SHR-A1811: intravenous infusion; Adebrelimab Injection: intravenous infusion; Capecitabine Tablets: oral administration Fluorouracil Injection: intravenous infusion

DRUG

Trastuzumab + Pembrolizumab + CAPOX( Capecitabine Tablets + Oxaliplatin) or FP (Fluorouracil Injection+Cisplatin)

Trastuzumab : intravenous infusion; Pembrolizumab: intravenous infusion; Capecitabine Tablets: oral administration; Oxaliplatin: intravenous infusion; Fluorouracil Injection: intravenous infusion; Cisplatin: intravenous infusion;

Trial Locations (2)

110001

RECRUITING

The First Hospital of China Medical University, Shenyang

200032

RECRUITING

Zhongshan Hospital，Fudan University, Shanghai

All Listed Sponsors
lead

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

INDUSTRY

NCT07118527 - A Phase III Study of SHR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Untreated Patients With Gastric or Gastroesophageal Junction Adenocarcinoma | Biotech Hunter | Biotech Hunter